Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 6/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.35 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | ATG7 | O95352 | 1/20 | 0.35 |
| ▸ | UBA7 | P41226 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184238 | 0.83 | NAE1 (0.35) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL867112 | 0.81 | EGFR (0.34) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL868210 | 0.80 | NAE1 (0.37) | NAE1UBA3UBA6SAE1ATG7 | |
| SCHEMBL866638 | 0.77 | EGFR (0.34) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL866635 | 0.76 | NAE1 (0.56) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL868078 | 0.74 | NAE1 (0.44) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL10149373 | 0.72 | EGFR (0.39) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL10184236 | 0.72 | AURKA (0.38) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL865690 | 0.71 | AURKA (0.42) | NAE1UBA3UBA6SAE1CA2 | |
| SCHEMBL867518 | 0.71 | AURKA (0.42) | NAE1UBA3UBA6SAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | NAE1 2/4885UBA3 3/4885UBA6 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.